Prospects for prostate cancer imaging and therapy using high-affinity TRPM8 activators

Benjamin Beck1, Gabriel Bidaux, Alexis Bavencoffe

  • 1Inserm, U800, Equipe Labellisée par la Ligue Contre le Cancer, Villeneuve d'Ascq F-59650, France.

Cell Calcium
|September 5, 2006
PubMed

Insights

Researchers identified novel, high-affinity ligands for the TRPM8 channel, a key player in prostate cancer. One compound, WS-12, shows significantly greater affinity than menthol, offering potential for cancer diagnosis and therapy.

Area of Science:

  • Molecular biology
  • Pharmacology
  • Oncology

Background:

  • Transient receptor potential melastatin 8 (TRPM8) channels are activated by cold and cooling agents.
  • TRPM8 is implicated in prostate cancer pathophysiology, with increased expression and involvement in apoptosis.
  • TRPM8 serves as a potential tumor marker and therapeutic target for prostate cancer.

Purpose of the Study:

  • To investigate the action of "WS" compounds on TRPM8 channels.
  • To identify novel TRPM8-specific ligands with high affinity.
  • To compare the affinity of new ligands to menthol and icilin.

Main Methods:

  • Screening of "WS" compounds for TRPM8 channel activity.
  • Affinity comparison of identified ligands with menthol and icilin.
  • Assessment of a fluorinated WS-12 analog's activity.

Main Results:

  • Identification of new TRPM8 agonists from the "WS" compound series.
  • WS-12 demonstrated significantly higher affinity than menthol (EC50 approx. 2000 times lower).
  • A fluorinated WS-12 derivative retained 75% of the parent compound's activity.

Conclusions:

  • WS-12 is the highest-affinity TRPM8 ligand identified to date.
  • Novel TRPM8 ligands hold potential for prostate cancer diagnosis and therapy.
  • Radiohalogen incorporation into these ligands could facilitate imaging and treatment strategies.

Related Concept Videos